SUSTAIN-6 specifically looked at cardiovascular outcomes including renal endpoints
Rebound fat gain is a concern users raise frequently, but the evidence doesn't support it as a direct peptide cessation effect
The 50 mg format is ideal for large-scale research programs, extended experimental series, and multi-phase studies requiring consistent peptide supply and reproducibility
Your individual potential depends on starting weight, genetics, and medication responsiveness
When GLP-1 medicines may be beneficial A person may be suitable if they: Have strong appetite signals that make weight control difficult Have tried structured diet and activity plans without enough progress Have health conditions that improve when weight is reduced Need support managing portion sizes and cravings These treatments work best as part of a complete plan, not on their own
Many patients starting semaglutide injections ask when they will notice the medication working